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The class B secretin GPCR (SecR) has broad physiological effects, with target potential for
treatment of metabolic and cardiovascular disease. Molecular understanding of SecR binding
and activation is important for its therapeutic exploitation. We combined cryo-electron
microscopy, molecular dynamics, and biochemical cross-linking to determine a 2.3 Å struc-
ture, and interrogate dynamics, of secretin bound to the SecR:Gs complex. SecR exhibited a
unique organization of its extracellular domain (ECD) relative to its 7-transmembrane (TM)
core, forming more extended interactions than other family members. Numerous polar
interactions formed between secretin and the receptor extracellular loops (ECLs) and TM
helices. Cysteine-cross-linking, cryo-electron microscopy multivariate analysis and molecular
dynamics simulations revealed that interactions between peptide and receptor were dynamic,
and suggested a model for initial peptide engagement where early interactions between the
far N-terminus of the peptide and SecR ECL2 likely occur following initial binding of the
peptide C-terminus to the ECD.
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G protein-coupled receptors (GPCRs) are the largest familyof cell surface receptors and pre-eminent drug targets.There are four major subclasses of GPCRs: A, B, C, and F.
Peptide hormone class B GPCRs are a subfamily of GPCRs that
are particularly important in physiology and disease, since their
endogenous ligands play major roles in homeostatic control of
bone and energy metabolism, cardiovascular, and immune
responses1. Consequently, these receptors are important targets
for treatment of disorders of these functions. Class B GPCRs
encompass targets for approved drugs that treat diabetes, obesity,
osteoporosis, hypercalcemia, and Paget’s disease, all of which are
major global health burdens1. However, targeting these receptors
for therapeutic benefit is suboptimal1. Class B receptors are also
pleiotropically coupled and we currently lack a complete under-
standing of the breadth of signaling that is required for specific
clinical efficacy and how this can be optimally achieved.
The class B secretin GPCR (SecR) is renowned for its physio-
logical role as a regulator of pancreatic and biliary ductular epi-
thelial secretion2. Subsequent studies, including phenotypic
analysis of mice genetically engineered to have no secretin peptide
(Sec−/−)3 or receptor (SecR−/−)4, have revealed a much broader
profile of action and the potential for secretin receptor agonists to
fill key unmet clinical need across a range of diseases including
obesity and diabetes, as well as heart failure5, among the most
prevalent, costly, and debilitating public health problems. For
example, secretin produces satiety to reduce body weight6, has
direct thermogenic effects on adipocytes7 and elicits a glucose-
sensitive incretin effect to help normalize glucose8. Further,
secretin increases cardiac output and stroke volume and reduces
systemic vascular resistance, while increasing coronary, renal,
mesenteric, and carotid flow, providing benefits for heart failure5.
Understanding the molecular basis for secretin receptor binding
and activation is therefore important for therapeutic exploitation
of this receptor.
In this study, we have combined single-particle cryo-electron
microscopy, molecular dynamics (MD), and biochemical cross-
linking to determine the structure and dynamics of secretin
bound to the human SecR:Gs protein complex. While there are
parallels to other active class B peptide hormone receptor struc-
tures, the SecR demonstrates a unique organization of the
receptor extracellular domain (ECD) to the 7-transmembrane
(TM) domain core, forming more extended interactions than
other class B GPCRs. Secretin formed numerous polar interac-
tions between the N-terminal half of the peptide and receptor
extracellular loops (ECLs) and TM helices, with the importance of
these interactions supported by mutagenesis data. Cysteine-cross-
linking analysis and MD simulations revealed that the interac-
tions between SecR and secretin were dynamic, and suggested a
model for initial peptide engagement where early interactions
between the far N-terminus of the peptide and the SecR ECL2
likely occur following initial binding of the peptide C-terminus to
the receptor ECD.
Results
Cryo-EM determination of the secretin:SecR:Gs complex. The
human SecR was modified to replace the native signal sequence
with that of hemagglutinin (HA), followed by a Flag epitope, and
inclusion of a C-terminal His tag, both flanked by 3C cleavage
sites, as previously described for other class B GPCRs9. The
expression construct maintained an equivalent ability to wild-
type receptor to signal to Gs-mediated cAMP production
(Fig. 1a). Complexes of the receptor with dominant negative GαS:
Gβ1γ29,10 were formed by the addition of 1 μM secretin. Two
distinct datasets were collected >12 months apart, however, the
biochemistry for formation of the two complexes was equivalent,
except that the Gαs protein contained an additional A366S
mutation (DNGαsv2) for the latter complex10,11. The complexes
exhibited a monodisperse peak on size-exclusion chromatography
(SEC) (Fig. 1b, Supplementary Fig. 1a, right panels), following
purification by anti-Flag antibody chromatography and an initial
SEC separation (Fig. 1b, Supplementary Fig. 1a, left panels),
containing each of the component proteins (Fig. 1c, Supple-
mentary Fig. 1b). The complexes were imaged by single-particle
cryo-EM. The first data set yielded a map of FSC 0.143, 4.3 Å
global resolution, and this was used to build the initial model used
for MD simulations (Supplementary Fig 1d–f). A second data set
was collected using improved vitrification and imaging protocols
established subsequently in the Danev laboratory11. Only the
high-resolution structure is described below; however, the origi-
nal model derived from the lower resolution map exhibited high
overall concordance with the model constructed into the high-
resolution map (Supplementary Fig. 1g–i).
Although there was preferred orientation of the particles
(Fig. 1d), these data were processed to yield final maps with global
resolutions, by gold standard FSC 0.143, of 2.3–2.5 Å (Fig. 1e, f).
The highest local resolution was present for the receptor
transmembrane domain, G protein, and for the peptide N-
terminus that binds deep into the receptor core, and this was
reflected in the 2.3 Å (tight mask excluding micelle and Gs α-
helical domain (AHD)) and 2.4 Å (wide mask) maps (Fig. 1h, i).
An atomic model of the complex was built into the electron
density map using MD-guided fitting and manually inspected and
adjusted using geometric constraints (Supplementary Fig. 2).
Both the high-resolution map with the tight mask (Fig. 1g, h) and
the receptor-focused map (Fig. 1g, i) were used in modeling, since
the latter had better resolution for the loops and peptide C-
terminus (Supplementary Fig. 2). Overall, the maps allowed
accurate placement of side-chain rotamers for most of the
receptor transmembrane domain, all ECLs, ICL1 and ICL2, and G
protein, as well as the N-terminus of the peptide (Supplementary
Fig. 2); however, the ECD resolution did not allow unambiguous
placement of side chains, and only the backbone was modeled
between R30ECD (the first modeled amino acid) and S130ECD.
Similarly, residues 254–263 of Gαs were only modeled as a
backbone trace, while the AHD of Gαs (62–204) was omitted
from the model. We also performed extensive MD simulations
(3 × ~1 μs) to derive further insight into binding dynamics of the
secretin peptide to the receptor and engagement of the receptor
with the Gs protein.
General features of the secretin:SecR:Gs complex. The active
SecR complex exhibits the key features of active class B GPCRs
with outward movement of the tops of TM6/TM7/ECL3, lateral
movement of TM1 and reordering of ECL2 into a common fold
(Fig. 1j, k, Supplementary Fig. 3)12, paralleled by a large outward
movement of TM6 at the base of the receptor to accommodate G
protein binding (Supplementary Fig. 3c). The secretin peptide
forms an extended α-helix that exits the receptor almost per-
pendicular to the membrane, extending out of the transmem-
brane domain core (Figs. 1j, k and 2, Supplementary Fig. 4). The
N-terminus terminates above the conserved class B receptor
central polar network, similar to the related GCG family of
peptides at their cognate receptors9,12,13 and forms extensive
interactions with TM1, TM2, TM5, TM6, and TM7 (Supple-
mentary Fig. 3D, Supplementary Tables 1–4).
SecR ECD. The ECD orientation of class B GPCRs is one of the
most variable features observed in active structures12, and we
have speculated that this may be important in the activity of the
individual receptors. The N-terminal helix of the ECD in the SecR
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extends deep towards the ECL regions of the receptor core where
it makes interactions with ECL1, ECL2, and the secretin peptide
that likely stabilize the overall dynamics of the ECD (Figs. 1k
and 2, Supplementary Fig. 5b–d). Fine angular sampling using the
receptor-focused mask identified two distinct classes with altered
positioning of the ECD, and this likely contributes to the lower
overall resolution in the consensus maps (Supplementary Fig. 5).
Dynamic motions of the receptor are discussed further below.
The most closely related orientation of the ECD is seen with the
GCG receptor family that are the most evolutionarily conserved
with SecR, and the far N-terminal helix of these receptors also
extends to the top of the ECLs, though not to the extent of the
SecR (Fig. 2a). While the PAC1 and PTH1 receptor ECDs exhibit
partial overlap in orientation to the SecR, the far N-terminus is
oriented further away from the receptor core (Fig. 2b). Interest-
ingly, the location of the ECD for the CRF receptor family
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overlaps closely with that of the SecR, but they do not have an
equivalent N-terminal α-helix and thus lack equivalent interac-
tions with the receptor core (Fig. 2c), and this likely accounts for
the lower relative resolution of the ECD in structures of these
receptors12,14. The calcitonin family receptors have a markedly
distinct ECD orientation from other class B GPCRs that is
enabled by an unstructured peptide C-terminus (Fig. 2d)15. These
receptors form prominent interactions with the receptor activity-
modifying protein (RAMP) family to yield unique receptor
phenotypes for binding of CGRP, adrenomedullin (AM), amylin,
and related peptides16. Interestingly, the location of the RAMP
ECD overlaps the position of the SecR ECD (Fig. 2d, Supple-
mentary Fig. 4). Although the SecR can also interact with
RAMP317, the structural data indicates that it is unlikely to
engage via an equivalent (TM3, TM4, TM5, and ECD) interface
to that of the CT family receptors15. This is consistent with our
previous work illustrating that it is the transmembrane domain,
and not ECD, which is most critical for RAMP3 and SecR
dimerization, and that TM6 and TM7 of SecR may form the site
of interaction with the RAMP3 TM domain17. As all class B
GPCR peptides, except those of the CT receptor subgroup, have
C-terminal extended α-helices, and thus a principally vertical
ECD orientation, similar to SecR (Fig. 2, Supplementary Fig. 4), it
is likely that the RAMP engagement that is seen with most other
class B GPCRs would follow an interaction model similar to SecR.
Secretin binding site. Dynamics of the SecR complex was
examined by 3D multivariate analysis of the cryo-EM data and in
the long time-scale MD simulations. Separation of the con-
formational variance in the cryo-EM data into the three main
principal components revealed that receptor exhibits twisting and
rocking motions that are apparent relative to the G protein. These
motions are similar to but less dynamic than those previously
observed for the TM core of AM receptors11. Across each of the
principal components, the receptor ECD exhibited higher relative
motion than the rest of the receptor but was nonetheless
restricted by interactions with the peptide and receptor core,
where the far N-terminus made dynamic interactions with the
ECLs; however, no substantial translational motions were evident
(Video 1). This contrasted to the much broader motions that were
previously observed for the ECD of AM receptors using equiva-
lent analyses11. Importantly, the cryo-EM conformational var-
iance data were consistent with the MD simulations where,
overall, the receptor TM domain core and the secretin peptide
exhibited limited dynamic motion of the peptide backbone,
whereas the ECD exhibited higher mobility that was independent
of motions of the rest of the receptor and peptide (Fig. 3a,
Video 2). Within the ECD, those regions that maintained stable
contacts with the secretin peptide had substantially less motion
than the rest of the ECD that lacked these constraints (Supple-
mentary Tables 2–4, Fig. 3b, Video 2).
Atomic modeling into the static consensus high-resolution
maps revealed specific details on the interactions between secretin
and SecR and these are reported in (Supplementary Table 1,
Supplementary Fig 6a, b). To better understand these interac-
tions, we interrogated their stability in a simulated POPC lipid
environment over microseconds of MD. The secretin peptide
forms an amphipathic α-helix and contains many polar and
charged amino acids, and perhaps not surprisingly forms
extensive stable and transient H-bond interactions over the
course of the microsecond simulations, particularly with the
receptor core and ECLs. The first three amino acids of secretin are
among the most critical for receptor activation18,19, and each of
these residues forms critical H-bond interactions with the
receptor (Supplementary Table 1, Supplementary Fig. 6a, b). In
the simulations, His1P and Ser2P (peptide residues are recorded
using the three-letter amino acid code, with sequence numbers
superscripted) are predicted to form stable backbone and/or side-
chain interactions with E3737.42 (superscript numbers refer to the
Wootten et al. class B numbering system20) deep within the
receptor core, with His1P forming additional transient interac-
tions with R2995.40, Y2303.44, Q2233.37, and potential weak
interactions with the backbone of ECL3 residues E363 and M366
(Fig. 4a, Supplementary Tables 2, 3). Asp3P is predicted to form
relatively stable interactions with R1882.60 of the central polar
network, as well as with R2995.40 and Y1461.43 (Fig. 4a,
Supplementary Table 2); the latter are distinct from the
interactions observed in the static consensus structure and
highlight the likely importance of conformational dynamics in
the action of peptide agonists. The identified class B receptor
residues form conserved interactions with most cognate class B
peptides12, and prior mutagenesis has also demonstrated
importance of at least Y1461.43, R1882.60, and Q2233.37 for
peptide function in the SecR21–23. Gly4P, Thr5P, Thr7P, and Ser8P
are predicted to form potential weak H-bonds with residues
within ECL2 of the SecR, with the most persistent interactions
occurring between Ser8P and N289ECL2 (Fig. 4a, Supplementary
Tables 2, 3). Glu9P is predicted to form a stable interaction with
R1351.32, while the cluster of basic residues, Arg14P, Arg18P, and
Arg21P that reside on one face of the secretin peptide form
extensive electrostatic and H-bond interactions with a cluster of
acidic Asp residues within or adjacent to ECL1, D1962.68,
D203ECL1, D204ECL1, and D209ECL1 (Fig. 4a, Supplementary
Tables 2, 3). In contrast to the extensive polar interactions with
the receptor core, only relatively few H-bond interactions were
predicted between the secretin peptide and SecR ECD; these were
between Glu15P and R30ECD, Gln24P and N120ECD, and the
backbone of Leu26P, and to a lesser extent Val27P and N72ECD
(Fig. 4a, Supplementary Tables 2, 3), although these interactions
Fig. 1 Cryo-EM structure of the secretin:SecR:DNGαsv2:Nb35 complex. a Pharmacology of the expression construct for HA-SecR versus WT-SecR (WT-
SecR, pEC50 11.0 ± 0.1; HA-SecR, pEC50 10.6 ± 0.2; n= 4). b SEC trace of post FLAG-affinity column elution (left panel), the complex peak (gray, dotted
lines) was isolated and used for cryo-EM imaging, with the right panel illustrating stability of the complex following one cycle of freeze-thawing.
c Coomassie stain of the purified complex separated by PAGE (right panel). d 3-D histogram representation of the Euler angle distribution of all the
particles used in the reconstruction overlaid on the density map drawn on the same coordinate axis (shown from the front and 90° rotated). e Gold
standard Fourier shell correlation (FSC) curves for the global, postprocessed map using a tight mask showing the overall nominal resolution of 2.3 Å.
f Corrected FSC curves of maps using different masking: consensus refinement, postprocessed using a tight mask (excluding ECD and micelle, 2.3 Å, in
purple), consensus refinement, postprocessed using a wide mask (2.4 Å, in cyan), and local refinement with using a receptor-only mask (2.5 Å, in gray).
g Masks used for calculating FSC curves in f, displayed onto the global refinement map (colored according to f). h Local resolution-filtered EM map
displaying local resolution (in Å) colored from highest resolution (blue) to lowest resolution (red) of the global map. i Local resolution-filtered EM map
displaying local resolution (in Å) of the receptor-only refinement. j Global map (dark gray) overlaid with receptor-only map (gray transparent) containing
the backbone model of the complex in ribbon format; SecR (dark green), secretin (dark red), G protein α-subunit (gold), β-subunit (cyan), γ-subunit (dark
purple), and Nb35 (white). k Ribbon representation of the secretin:SecR:DNGαsv2:Nb35 complex colored according to j.
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Fig. 2 Comparison of SecR and other class B GPCR Gs-coupled active structures. Overlay of secretin (dark red) and SecR (dark green) and different class
B GPCR subfamilies emphasizing the position of the receptor ECD and location of the far N-terminus of the receptor (highlighted by red circle (a) or red
arrows (b–d). a Glucagon (GCG, pink; GCGR dark blue) and GLP-1 receptors (GLP-1, dark pink; ExP5, red; GLP-1R, dark gray). b PTH1 (PTH, pink; PTH1R,
light gray) and PAC1 receptors (PACAP38, pale green; PAC1R, light blue). c CRF1 (CRF, dark green; Urocortin (Uro), orange; CRF1R, blue) and CRF2
receptors (Uro, orange; CRF2R, green). d Calcitonin (sCT, orange; CTR, purple) and CGRP (CGRP, coral; CLR, cyan; RAMP1, green) receptors. Helical
secondary structure is shown as cylinders; beta sheets are displayed as flattened arrows.
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were predicted to limit mobility within the ECD as noted above
(Fig. 3b).
In addition to the polar interactions described above, there
were extensive predicted hydrophobic interactions between the
peptide and receptor, particularly from the lipophilic face of the
peptide (Phe6P, Leu10P, and Leu13P) that made broad interactions
with aliphatic side chains of residues in TM7 and TM1 (L3747.43,
H1361.33, L1391.36, L1421.39, and K1431.40) (Fig. 4b, Supplemen-
tary Table 4). Within the ECD there was a hydrophobic
surface comprised of the aliphatic side chains of L28ECD,
R30ECD, L31ECD, V34ECD, and L38ECD of the N-terminal α-
helix, and loop residues N72ECD, I73ECD, F92ECD, and L96ECD
that provide the principal ECD binding groove for the peptide
and interacted with Leu19P, Gln20P, Leu22P, Leu23P, Leu26P, and
Val27P (Fig. 4b, Supplementary Table 4). Moreover, the simula-
tions predicted that Arg18P and Leu22P could form interactions
with both ECL1 and the ECD (Supplementary Table 4)
potentially contributing to stability of the location and dynamics
of ECD-core interactions.
We have previously performed cysteine scanning mutagenesis
of ECLs 1, 2, and 3 and analyzed these for effect on cell surface
receptor expression, secretin affinity and secretin efficacy in
cAMP production23,24 (Supplementary Table 5). In the current
study this analysis was extended to include residues at the top of
TM1 (Supplementary Table 6). Strikingly, mutation of residues in
ECL1 and its proximal extension to TM2 had the greatest impact
on both secretin affinity and potency (Supplementary Fig 7a, b),
consistent with the key role of this receptor region in interactions
with both the secretin peptide and the far N-terminus of the ECD.
Similarly, receptor residues in ECL2 and ECL3 that formed side-
chain interactions with the peptide impacted on either peptide
affinity or potency (Supplementary Fig. 7a, b). Interestingly,
although mutations to residues in TM1 had relatively limited
impact on secretin potency (Supplementary Fig. 7a), there was
increased apparent affinity of secretin with mutation of residues
towards the apex of TM1 but which were mostly oriented away
from the peptide interaction interface (Supplementary Fig. 7b). It
is possible that substitution with the small amino acid cysteine
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may have increased flexibility of this region to allow more
favorable peptide interactions.
Cysteine cross-linking of Cys-substituted secretin peptides.
Disulfide cross-linking between cysteines requires both spatial
proximity and appropriate geometry to occur25. As such, it has
become a useful tool to study trajectories of protein-protein
interaction that can include intermediate states involved in pep-
tide binding. We have previously determined the efficiency of the
cross-linking of N-terminally Cys-substituted secretin peptide
analogs at positions 2, 5, 6, and 7 to SecR with individual Cys
mutation throughout the ECLs23,24 (Supplementary Table 7), and
these can now be mapped onto the active SecR structure. In the
current study, we have extended our analysis to include amino
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acids in the upper segment of TM1, as well as comparison of
cross-linking patterns to radiolabelled analogs of the antagonist
peptide secretin (c[E16, K20], I17, Cha22, R25)sec(5–27), cysteine-
substituted at positions 5, 6, and 7 (Figs. 5 and 6, Supplementary
Tables 8, 9, Supplementary Figs 8–13). No cross-linking was
observed within TM1 for any of the agonist analogs (Supple-
mentary Fig. 13). In contrast, cross-linking to Y1461.43 was
observed for both the Cys5P and Cys7P antagonist peptides
(Supplementary Table 9, Supplementary Fig. 13). No cross-
linking of antagonist peptides was observed within ECL1 (Sup-
plementary Table 8), consistent with observations for the agonist
analogs23,24 (Fig. 5). In contrast, extensive cross-linking was
observed within ECL2 (Supplementary Fig. 10) and, in particular,
ECL3 (Fig. 5A). For the Cys5P analog, efficient cross-linking
(>25% cross-linking efficiency relative to the highest signal for
any of the peptides) was observed for SecR residues Y1461.43,
F3586.56/ECL3, A359ECL3, F360ECL3, and S361ECL3. The Cys6P and
Cys7P also exhibited efficient cross-linking to F358ECL3-S361ECL3,
with the Cys6P also cross-linking efficiently to F3727.41 and
E3737.42. Perhaps unsurprisingly, there was considerable overlap
in the location of cross-linking identified for cysteine substitution
at equivalent positions in the agonist and antagonist peptides.
Nonetheless, important differences occurred in the sites of highest
cross-linking efficiency and indeed in the extent of SecR residues
that were cross-linked for the two peptides23,24 (Supplementary
Tables 7–9, Figs. 5, 6). In general, more cross-linking was
observed for the agonist substituted peptides that may reflect
higher mobility of the receptor bound to the agonist and/or
additional conformational sampling due to transducer engage-
ment. In addition, the most efficient site(s) of cross-linking within
ECL3 tended to move from the membrane proximal segment of
TM6, for the antagonist, to mid-ECL3 or the TM7 proximal
segment for the agonist peptides23,24 (Fig. 5c), and this is also
consistent with ECL3 being the most conformationally divergent
among the solved class B GPCR structures12.
While cross-linking occurred between the peptide cysteine and
receptor residues that were proximal in the active, G protein-
bound, structure, in all cases, additional sites of efficient cross-
linking were observed, both for agonist and antagonist peptides
(Fig. 6). MD simulations to probe partial unbinding and
rebinding provided heatmaps for residue proximity that were
consistent with most sites of cross-linking identified in the
biochemical analysis (Fig. 7a, b, Video 3). However, they did not
explain interactions observed for some of the SecR residues in
ECL2 (e.g. W295ECL2), although this could potentially be
accounted for by a binding interaction model where, early in
engagement, the peptide C-terminus engaged with the receptor
ECD while the peptide was almost horizontal with the membrane
(Fig. 7c); this would site the peptide N-terminus in proximity to
ECL2 during early phases of binding. Alternatively, the peptide
may have a more disordered structure during initial binding
allowing simultaneous engagement of the peptide N-terminus
and ECL2, and peptide C-terminus and receptor ECD. While
speculative, others have previously proposed models of peptide-
membrane interaction that could promote peptide secondary
structure26, potentially providing a mechanistic reason for why
this might occur. In this model, the initial peptide engagement
would disrupt constraining interactions of the ECD and
membrane core to provide the ECD flexibility required to allow
key interactions between the peptide N-terminus and the receptor
core to form.
The SecR-G protein interface. In the static consensus map, SecR
forms extensive polar and nonpolar interactions with the G
protein, predominantly with the α5-helix of Gαs (Supplementary
Table 1, Supplementary Fig 6c, d). As for the secretin:SecR
interface, we have used the MD simulations in POPC to inter-
rogate interaction dynamics between SecR and Gs. Not surpris-
ingly, the interactions between the SecR and Gs heterotrimer were
similar to those previously reported for other class B GPCRs12,
with both polar and hydrophobic interactions between the Gαs
protein and TMs 2, 3, 5, and 6 (Supplementary Tables 10–12,
Fig. 8, Video 4). However, while most other class B GPCRs
exhibit contacts between Gαs and the base of TM7 and junction
with helix 8 (H8), there were few stable interactions between this
domain of the SecR and the G protein. This was most similar to
the PTH1R that also lacked substantive interactions with the
TM7/H8 junction12,27. For the SecR, stable H-bond or salt-bridge
interactions were predicted to occur principally between ICL3,
and bottoms of TM5 and TM6 and the Gα subunit, with more
limited interactions between Q35, R38, Q384 and R380, and ICL2
or the backbone of the nearby L2443.58 (Supplementary Tables 10,
11, Fig. 8). The polar interactions with TM5/ICL3/TM6 were
predominantly to the α5-helix of Gαs, with more limited inter-
actions predicted to occur with R342 and D323 in the Gα protein.
Similar to other class B GPCRs, there were also predicted inter-
actions between the Gβ subunit and the receptor, with the most
prominent interactions being between D312β and K4018.48 in H8
and R169 in ICL1, which were also observed in the cryo-EM
consensus map (Supplementary Table 1, Supplementary
Tables 10–12, Fig. 8).
In the SecR EM map, there is clear density for F248ICL2 that is
located in the junction between the Gs αN helix and α5-helix
(Supplementary Fig. 14a). A positionally equivalent aromatic
(Phe or Tyr) is seen in most active, G protein-complexed, class B
GPCR structures solved to date12, as well as the class A Gs-
coupled EP2 and β2-adrenergic receptors28,29, although select
class B GPCRs have a lipophilic Leu, and the GIPR has a distinct
Fig. 4 Interactions between SecR and secretin during MD simulations. a Hydrogen bonds between SecR and secretin. The total occupancy (% frames) of
each atom is plotted onto the equilibrated complex according to a color scale, with SecR atoms never involved in white, secretin atoms never involved in
black and atoms highly involved in magenta. The peptide (ball and stick residues indicated with solid lines) is depicted as black, partially transparent ribbon,
while the receptor (stick residues indicated with dashed lines) is shown as white, partially transparent ribbon. The central image specifies the relative
perspectives from the right and left sides. Right side view) Hydrogen bonds between the N-terminus of secreting and the TM bundle of the SecR; the main
interactions involved S2sec—E3737.42, D3sec—R1882.60, and E9sec—R1351.32. Left side view) Hydrogen bonds between the C-terminus of secretin and the
ECL1 of the SecR; main intermolecular interactions involved R14sec, R18sec, R21sec on the peptide, and D203ECL1, D204 ECL1, and D209 ECL1 on the receptor.
b Contacts between SecR and secretin. The total occupancy (% frames) of each atom is plotted onto the surface of the equilibrated SecR according to a
color scale, with SecR atoms never involved in blue, and atoms highly involved in red. The peptide is shown as transparent gray ribbon. The central image
specifies the relative perspectives from the top and side. Top view) Contacts between secretin and the TM bundle of the SecR (residues from L28ECD to
E133ECD have been removed for clarity); the bottom figure shows the ribbon representation as reference. Main interactions involved TM1 (R1351.32,
H1361.33, and L1391.36), TM2 (L1992.71), ECL2 (D287ECL2 and I288ECL2), TM5 (D2995.40), and TM7 (E3737.42). Side view) Contacts between secretin C-
terminal and SecR; the bottom figure shows the ribbon representation as reference. Main interactions involved ECL1 (D203ECL1, D204ECL1, and D209 ECL1),
and ECD (R30ECD, L31 ECD, V34 ECD, F92ECD, I73ECD, and L96ECD).
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sequence12. It is hypothesized that interactions between ICL2 and
the G protein may contribute to G protein activation, contribut-
ing to conformational changes in the G protein linked to GDP
release28. Interestingly, during the course of the simulations,
F248ICL2 rapidly exits the αN/α5 junction (Supplementary
Fig. 14b, c, Video 4) suggesting that the ICL2-G protein interface
is dynamic, and it is possible that the observed orientation of the
ICL2 in the consensus map may be partially constrained by the
tools used to stabilize the Gα-Gβγ interface (Nb35, DNGαs),
although Nb35 was also present in the simulation.
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Fig. 5 Overview of cysteine-cross-linking by analogous cysteine-substituted agonist and antagonist secretin peptides. a Cysteine trapping of secretin
receptor ECL3 cysteine replacement mutants with 125I-labeled Cys5- or Cys6-containing secretin antagonist analogs. Shown are typical autoradiographs of
10% SDS–PAGE gels used to separate the products of cysteine trapping of the indicated ECL3 SecR cysteine replacement mutants transiently expressed in
COS-1 cells for each of the noted cysteine-containing secretin antagonist probes, under nonreducing (top panel) and reducing (bottom panel) conditions.
Autoradiographs are representative of a minimum of three independent experiments. Densitometric analysis of data from three similar experiments for
each probe is shown (middle panel), with intensities representing the percentages of the signal for the maximal labeling of a residue within ECL3 by that
probe. b Illustration of the difference of labeling within the extracellular loops of the cysteine-substituted secretin receptor mutants by cysteine-containing
antagonist (left hand panels) and agonist (right hand panels) probes. Blue colored residues are those with most efficient labeling (>50% of the highest
efficiency label), with the highest labeled residue denoted with a blue asterisk. Red colored residues denote those that cross-linked with intermediate
efficiency (25–50% of the highest efficiency label). c Schematic illustration of the major shifts in residue labeling between equivalent agonist and
antagonist probes.
a b
Cys7_ag
Cys6_ag
Cys5_ag
Cys2_ag Cys2_ag
Cys5_agCys5_antag Cys5_antag
Cys6_agCys6_antag Cys6_antag
Cys7_agCys7_antag Cys7_antag
Fig. 6 Mapping of cysteine cross-linking data onto the active SecR structure. a Side view. Left panel, secretin peptide analog; Middle panel, agonist cross-
linking pattern; Right panel, antagonist cross-linking pattern. b Magnified view looking into the SecR TM core. Left panel, agonist cross-linking pattern;
Middle panel, antagonist cross-linking pattern; Right panel, secretin peptide analog. Peptides are displayed in ribbon format with x-stick representation of
side chains, colored gray. The position of cysteine substitution is shown in colored cpk format (Cys7, dark blue; Cys6, purple; Cys5, red; Cys2, orange). The
SecR is shown in ribbon format with the location of the cysteine mutants displayed in combination cpk and surface representation. Sites of cross-linking are
colored according to the site of peptide substitution with dark shading for those with highest efficiency (>50% of the highest efficiency label) and those
with intermediate efficiency (25–50% of the highest efficiency label) having light shading.
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Discussion
In conclusion, the structure of the SecR provides new insight into
peptide binding and activation of class B GPCRs, and the dynamic
nature of these interactions. The SecR exhibited the strongest
interaction between the receptor ECD and the transmembrane core
of the receptor of all class B GPCRs structures solved to date, and
this likely contributed to higher relative stability of the ECD relative
to the rest of the receptor. This was reflected in the relative
a
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Simulated
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Fig. 7 Simulated partial unbinding and binding of secretin using well-tempered metadynamics simulations. a Overview of the simulation displayed in
Video 3. b Heat map of the interaction of secretin residues 2 (left panel), 5 (left middle panel), 6 (right middle panel), and 7 (right panel), equivalent to the
positions of cysteine substitution in cross-linking studies, with the SecR core during simulations. The position of the secretin residue in the cryo-EM
structure is displayed in green cpk representation, with the rest of the peptide displayed in transparent light gray ribbon format. The receptor core is shown
in surface representation colored according to frequency of interactions during the simulation. c Speculative schematic illustrating a potential binding
intermediate that could account for observed cysteine-cross-linking data prior to the peptide reaching its metastable position observed in the active, G
protein-coupled receptor structure.
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robustness of EM density for the ECD, compared to the rest of the
receptor, which is less well resolved in other class B GPCR struc-
tures. Combining structural data, MD simulations and biochemical
cross-linking data advanced understanding of the dynamics of the
interaction between secretin and its receptor and models for
potential initial engagement of peptide and receptor.
Methods
Constructs. Human SecR was modified to include an N-terminal HA tag and
FLAG epitope and a C-terminal 8×HIS tag; both of these are removable by 3C
protease cleavage. The construct was generated in both mammalian and insect cell
expression vectors. Previously described constructs for dominant negative human
Gαs (DNGαsv1)9, (DNGαsv2)10,11 human His6-tagged Gβ1, and Gγ29 in baculo-
virus expression vectors were used for complex generation.
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Insect cell expression. The SecR, DNGαsv1 or DNGαsv2 (the latter containing an
additional A366S mutation)10, Gβ1, and Gγ2 were expressed in Tni insect cells
(Expression Systems) using baculovirus. For the first preparation, cell cultures were
grown in ESF 921 serum-free media (Expression Systems) to a density of 4 million
cells/mL, and then infected with three separate baculoviruses at a ratio of 4:2:1 for
SecR, DNGαsv1, and Gβ1γ2, respectively. In the second preparation, cell cultures
were grown to a density of 3.3 million cells/mL, and then infected with the
baculoviruses at a ratio of 3:2:1 for SecR, DNGαsv2, and Gβ1γ2, respectively.
Culture was harvested by centrifugation ~48 h post infection and cell pellet was
stored at −80 °C.
Complex purification. Cell pellet was thawed in 20 mM HEPES pH 7.4, 50 mM
NaCl, 2 mM MgCl2 supplemented with complete Protease Inhibitor Cocktail
tablets (Roche) and benzonase nuclease (Merck Millipore). Complex formation
was initiated by addition of 1 μM human secretin (China Peptides), Nb35–His
(10 μg/mL) and apyrase (25 mU/mL, NEB); the suspension was incubated for 1 h at
room temperature. Membranes were collected by centrifugation at 30,000 × g for
30 min, and the complex from the membrane was solubilized by 0.5% (w/v) lauryl
maltose neopentyl glycol (LMNG, Anatrace) supplemented with 0.03% (w/v)
cholesteryl hemisuccinate (CHS, Anatrace) for 2 h at 4 °C in the presence of 1 μM
secretin and apyrase (25 mU/mL, NEB). Insoluble material was removed by cen-
trifugation at 30,000 × g for 30 min and the solubilized complex was immobilized
by batch binding to M1 anti-FLAG-affinity resin in the presence of 3 mM CaCl2.
The resin was packed into a glass column and washed with 20 column volumes of
20 mM HEPES pH 7.4, 100 mM NaCl, 2 mM MgCl2, 3 mM CaCl2, 1 μM secretin,
0.01% (w/v) LMNG, and 0.0006% (w/v) CHS before bound material was eluted in
buffer containing 5 mM EGTA and 0.1 mg/mL FLAG peptide. The complex was
then concentrated using an Amicon Ultra Centrifugal Filter (MWCO 100 kDa) and
subjected to SEC on a Superdex 200 Increase 10/300 column (GE Healthcare) that
was pre-equilibrated with 20 mM HEPES pH 7.4, 100 mM NaCl, 2 mM MgCl2, 1
μM secretin, 0.01% (w/v) MNG, and 0.0006% (w/v) CHS to separate complex from
contaminants. Eluted fractions consisting of receptor and G protein complex were
pooled and concentrated and stored at −80 °C. Purity and stability of the complex
following thawing was confirmed by fSEC. Final yield of purified complex was
approximately 0.125 mg/L of insect cell culture.
SDS–PAGE and western blot analysis. Sample collected from SEC was analyzed
by SDS–PAGE and western blot. For SDS–PAGE, precast gradient TGX gels (Bio-
Rad) were used. Gels were stained by Instant Blue (Expedeon). Antisera included
rabbit anti-Gs C-18 antibody (cat no. sc-383, Santa Cruz), goat anti-rabbit antibody
(800CW, LI-COR), mouse Penta-His antibody (cat no. 34660, QIAGEN), and goat
anti-mouse antibody (680RD, LI-COR).
Preparation of vitrified specimen. For the initial preparation, electron micro-
scopy grids (Quantifoil, 200-mesh copper R1.2/1.3) were glow-discharged for 90 s
using PELCO easiGlow. Four microliters of sample was applied on the grid in
Vitrobot Mark IV chamber (Thermo Fisher Scientific). The chamber of Vitrobot
was set to 100% humidity at 4 °C. The sample was blotted for 5.5 s with a blot force
of 25, and then plunged into ethane. For the second preparation, acetone pre-
washed electron microscopy grids (Ultrafoil R1.2/1.3 Au 300 mesh) were glow-
discharged and 3 μL of sample was applied to the grid in a Vitrobot Mark IV
chamber (Thermo Fisher Scientific), set to 100% humidity at 4 °C. The sample was
blotted for 10 s with a blot force of 19, and then flash frozen in liquid ethane.
Data acquisition. Initial datasets were collected on a Thermo Fisher Scientific
Titan Krios microscope operated at 300 kV equipped with a Gatan Quantum
energy filter, a Gatan K2 summit direct electron camera (Gatan). Movies were
taken in EFTEM nanoprobe mode, with 50-µm C2 aperture and pixel size of 0.86
Å. Each movie comprises 40 subframes with a total dose of 46 e− per Å, with
exposure time of 10 s with a dose rate of 3.42 e− pixel−1 s−1 on the detector. Data
acquisition was done using EPU software (Thermo Fisher Scientific) at −500 nm to
−1.9 µm defocus (200 nm step). Data from the second sample were collected on a
Titan Krios microscope operated at an accelerating voltage of 300 kV with a 50 μm
C2 aperture at an indicated magnification of 105,000 × g in EFTEM nanoprobe
mode and a spot size of 5. A Gatan K3 direct electron detector, positioned post a
Gatan Quantum energy filter (Gatan, Pleasanton, CA, USA) with a slit width of 25
eV, was used to collect movies in CDS mode. Movies were recorded as compressed
TIFFs in normal-resolution mode yielding a physical pixel size of 0.83 Å/pixel with
an exposure time of 5.011 s amounting to a total exposure of 52.9 e−/Å2 for at an
exposure rate of 7.27 e−/pixel/second that was fractionated into 71 subframes.
Defocus was varied in the range between −0.7 and −1.5 μm. Beam-image shift,
with beam-tilt compensation, was used to acquire data from nine surrounding
holes after which the stage was moved to the next collection area using a custom
SerialEM script30,31.
Data processing. For the initial sample, a total of 6500 movies were collected and
subjected to motion correction using MotionCor2 implemented in RELION
v.3.0.732. CTF estimation was done using Gctf software33 on nondose-weighted
micrographs. The particles were picked using cisTEM34. An initial model was made
using the common-line approach in EMAN235. Picked particles from cisTEM was
imported in RELION v.3.0.7. The particles were extracted using a box size of 240
pixels. A total of 1,200,000 picked particles were subjected to two rounds of 2D
classification, followed by 3D classification. After selecting the best-looking class,
with 159k particles, 3D auto-refinement was done followed by another round of 3D
classification without alignment. Lastly, 77,754 particles from the best-looking class
were subjected to 3D auto-refinement.
For the second sample, a total of 5600 movies were collected and subjected to
motion correction using MotionCor232 and CTF estimation was done using the
Gctf33 software on nondose-weighted micrographs, implemented in Relion v3.1-
beta36. The particles were picked using the automated procedure in crYOLO37 and
coordinates were imported into Relion. Subsequent data processing steps were
carried out using Relion v3.1-beta36. Particles were extracted initially using a box of
64 pixels, and after curation of particles in 2D and 3D classifications, re-extracted
using a final box size of 288. As an initial 3D reference, a previous GPCR complex
map was used and 60 Å low-pass filtered to prevent model bias. 3D references in
subsequent steps derived from the data itself. Subsequent rounds of 3D
classifications, 3D refinements, and 3D classification without angular and
translational alignment were used to create a homogenous set of ~350,000 particles
and was further subjected to Bayesian particle polishing and CTF refinements (as
implemented in Relion v3.1-beta). A final global 3D refinement using a wide mask
(including the entire complex and micelle) was carried out, resulting in a global
resolution (FSC= 0.143) of 2.4 Å. In postprocessing, different masks were applied
on the global refinement map, resulting in global resolutions (FSC= 0.143) of 2.4 Å
using the wide mask and 2.3 Å using a tight mask (excluding the ECD of the
receptor, AHD of the Gα protein and micelle) (Fig. 1e–g). To better resolve features
of the receptor loops and ECD, the global refinement map was subjected to 3D
classification and 3D refinement with fine angular sampling using a mask including
only the receptor and peptide (referred to as “receptor-only” refinement). The
receptor-only map resulted in a global resolution (FSC= 0.143) of 2.5 Å (Fig. 1f, g).
Local resolution estimates and maps were produced in Relion. All masks were
created with a custom script using e2proc3D.py from EMAN235.
Atomic model refinement. Initial models into the 4.3 Å map for SecR complex
were made with the Rosetta software package using the structure threading/com-
parative modeling and model relaxation protocols38. Fitting the Rosetta-generated
Fig. 8 Interactions between SecR and Gs protein during MD simulations. a Hydrogen bonds between SecR and Gs protein. The total occupancy (%
frames) of each atom is plotted onto the equilibrated complex according to a color scale, with SecR atoms never involved in white, G protein (Gα subunit)
never involved in orange, and G protein (Gβ subunit) never involved in cyan; atoms highly involved are magenta. The Gγ subunit is shown as green ribbon,
the Gα subunit (ball and stick residues indicated with solid lines) is depicted in orange, partially transparent ribbon, the Gβ subunit (ball and stick residues
indicated with solid lines) is shown as cyan, partially transparent ribbon; the SecR (stick residues indicated with dashed lines) is shown as white partially
transparent ribbon. The image on the right specifies the relative perspectives from the left and right sides. View from left side) View from the TM6/TM7/
TM8 side; View from right side) View from the TM1/TM2/TM3 side. Main hydrogen bonds involved SecR ICL1 (R169ICL1), TM5 (K3235.64) ICL3 (E328ICL3,
R330ICL3, T326ICL3, and R325ICL3), TM6 (R3396.37 and R3426.40), and H8 (K4018.56). On the G protein, the α subunit residues L394, Y391, R385, Q384,
D381, R342, D343, and Q35 were highly involved; the only β subunit side-chain engaged was D312. b Contacts between SecR and Gs protein. The total
occupancy (% frames) of each atom is plotted onto the surface of the equilibrated complex according to a color scale, with atoms never involved in blue,
and atoms highly involved in red. The central image specifies the relative perspectives from above and below. View from above) Contacts plotted on the G
protein surface (the bottom figure shows the ribbon representation as reference). Main interactions involved D312 (Gβ subunit), L394, E392, L393, Y391,
H387, R385, Q384, R380, R342, R38 (Gα subunit). View from below) Contacts plotted on the SecR surface (the bottom figure shows the ribbon
representation as reference). Main interactions involved ICL1 (R169ICL1), TM2 (R1742.46), ICL2 (F248ICL2), TM3 (L2433.57 and L2443.58), TM5 (K3235.64),
ICL3 (E328ICL3 and R330ICL3), TM6 (R3396.37 and R3426.40), and H8 (K4018.56).
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models in the cryo-EM density maps was performed with the MDFF routine in
namd239. The fitted models were further refined by rounds of manual model
building in coot40 and real-space refinement, as implemented in the Phenix soft-
ware package41. The density around the N-terminal ECDs was poorly resolved, and
this domain was modeled by further rounds of focused MDFF. As the maps in this
region were locally resolved to ~7 Å, only the backbone trace of the protein was
kept for deposition. Map and model statistics are detailed in Supplementary
Table 13. In the final model (PDB 6WI9), the first modeled residue is R30ECD and
the last modeled residue is L408H8. Residues R30ECD-S130ECD have only been
modeled as backbone trace, and amino acids S201ECL1-H211ECL1 have been
omitted from the model.
Based on the initial SecR model (PDB 6WI9), atomic coordinates were refined
into the new cryo-EM maps. The majority of the model (Gα, Gβ, Gγ, TMs, and
peptide N-terminus) was refined into the global postprocessed map using Phenix41
and manually inspected using Coot40. Lower resolution areas (in particular ECD,
ECL1, and ICL1-3) were furthermore refined using the receptor-only map, initially
by flexible fitting and refinement using Isolde42, Namdinator43 and namd239 and
finally by real-space refinement in Phenix and manual inspection in Coot. The
density of the ECD remained poorly resolved and therefore only the backbone of
the residues R30ECD-S130ECD was deposited. The final receptor model (PDB
6WZG) starts with residue R30ECD and ends with residue L4088.58 (with residues
30-130ECD of the receptor and 254–263 of the Gα protein modeled as backbone
trace). Amino acids from the AHD of the Gα protein (62–204) have been omitted
from the model.
Model residue interaction analysis. Interactions in the PDB (6WZG), between the
chains of the peptide and receptor (P:R) or receptor and G proteins (R:A and R:B),
were analyzed using the “Dimplot” module within the Ligplot+ program (v2.2)44.
Hydrogen bonds were additionally analyzed using the UCSF ChimeraX package, with
relaxed distance and angle criteria (0.4 Å and 20° tolerance, respectively). Additional
analyses and production of images were performed using the UCSF Chimera package
(v1.14) from the Computer Graphics Laboratory, University of California, San
Francisco (supported by NIH P41 RR-01081) and ChimeraX45 (support from
National Institutes of Health R01-GM129325).
3D variability analysis in Cryosparc. Particle stacks from the Relion global
consensus refinement as well as the refinement map were imported into the
Cryosparc v2 pipeline46. A consensus refinement in Cryosparc using the Homo-
geneous refinement tool and the imported Relion map as a reference volume was
produced, which was used as an input for the 3D variability analysis11. For the
variability analysis, the wide mask created automatically during refinement in
Cryosparc (including micelle) and a 2.8 Å filter was applied. The frames of the
three components generated in the 3D variability analysis were visualized in the
ChimeraX volume series, and movements were recorded as movies (see also:
Supplementary Fig. 15).
Mammalian cAMP assays. HA-secretin receptor-bearing COS-1 cells (CRL-1650,
American Type Culture Collection) were seeded at a density of 30,000 cells/well
into 96-well culture plates and incubated over-night in DMEM containing 5% FBS
at 37 °C in 5%CO2. cAMP detection was performed as previously described9. All
values were converted to cAMP concentration using a cAMP standard curve
performed in parallel and data were subsequently normalized to the response of
100 μM forskolin in each cell line. Data were analyzed by a 3-parameter logistic fit
in Prism v7 (GraphPad).
Peptides. Four cysteine-containing peptides were designed to incorporate a
cysteine for disulfide trapping in positions 5, 6, 7, and 10 of the secretin antagonist,
(c[E16, K20], Y10, I17, Cha22, R25)sec(5–27) (identified as Cys5, Cys6-, Cys7-, and
Cys10-antag) that we reported previously47. The Cys5-antag, Cys6-antag, and Cys7-
antag incorporated a tyrosine to replace the leucine in position 10 for radio-
iodination48, while a tyrosine was incorporated in position 26 of the Cys10-antag24
(Supplementary Fig. 8a). In addition, five cysteine-containing full-length secretin
agonist analogs we synthesized previously23,24 were also used in this study for
cysteine trapping of the 14 new cysteine mutants of the juxtamembranous region of
the amino-terminal domain of the secretin receptor (Supplementary Fig. 8a). All
peptides were synthesized and purified by China Peptides (Shanghai, China), with
their identities verified by electrospray ionization mass spectrometry.
Radioiodination. The secretin-like radioligand [Y10]secretin(1–27) used in com-
petition ligand binding assays, the newly synthesized Cys5-antag, Cys6-antag, Cys7-
antag, and Cys10-antag, as well as the five cysteine-containing full-length secretin
agonist analogs we synthesized previously23,24 were radioiodinated oxidatively
using procedures previously described49. This was done by incubating ~10 μg of
each peptide with 1 mCi Na125I in 0.1 M borate buffer (pH 9.0) and exposure for
15 s to the solid phase oxidant, N-chlorobenzenesulfonamide (Iodination bead)
(Pierce, Rockford, IL). The radioiodinated peptides were purified by reversed-phase
HPLC to yield specific radioactivities of ~2000 Ci/mmol using procedures we
previously described49.
Receptor constructs. The wild-type human secretin receptor (CHO-SecR) stably
expressed in Chinese Hamster Ovary (CHO-K1) cells (CCL-61, American Type
Culture Collection) that was established previously50 was used for characterizing
binding affinities and biological activities of Cys5-antag, Cys6-antag, Cys7-antag,
and Cys10-antag. This cell line was cultured at 37 °C in an environment containing
5% CO2 on tissue culture plasticware in Ham’s F-12 medium supplemented with
5% fetal clone II, and was passaged approximately twice a week.
For cysteine trapping studies with the Cys5-antag, Cys6-antag, Cys7-antag, and
Cys10-antag probes, wild type and a total of 61 previously characterized secretin
receptor constructs incorporating cysteine replacements for natural residues in
each of the positions of the three ECLs except for positions with a naturally
occurring cysteine were used. They were transiently expressed on COS-1 cells
(American Type Culture Collection, Manassas, VA) after transfection using the
polyethylenimine method as we have previously described23. Cells were maintained
in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented
with 5% fetal clone II and studied 48 h after transfection.
In addition, 14 new constructs incorporating cysteine replacements for natural
residues in each of the positions of the juxtamembranous region of the amino-
terminal domain of the secretin receptor ranging from residue Lys113 to Thr126
were generated. These cysteine mutants were prepared using an oligonucleotide-
directed approach with the QuikChange site-directed mutagenesis kit from
Stratagene (La Jolla, CA) (primers listed in Supplementary Table 14), with the
products verified by direct DNA sequencing. They were expressed transiently on
COS-1 cells (CRL-1650, American Type Culture Collection) after transfection
using a modification of the DEAE-dextran method for binding and biological
activity characterization51 or using the polyethylenimine method as we have
previously described for cysteine trapping experiments23. These constructs were
used in cysteine trapping studies using both agonist and antagonist cysteine
secretin probes.
Immunostaining. To determine levels of cell surface expression of the 14 new
constructs incorporating cysteine replacements for natural residues in each of the
positions of the juxtamembranous region of the amino-terminal domain of the
secretin receptor, immunostaining using an amino-terminal region secretin
receptor antibody was performed in COS-1 cells (CRL-1650, American Type
Culture Collection) transiently transfected with these constructs. This polyclonal
antibody52 was raised by GenScript (Piscataway, NJ) using the peptide antigen
representing amino acids 51–65 of the human secretin receptor (anti-hSecR(51–65)
that was synthesized and purified in-house.
Transfected cells grown on polylysine-coated glass coverslips in six-well plates
for 24 h were washed once with PBS followed by two washes with PBS containing
1% normal goat serum. Coverslips were then incubated for 1 h at room
temperature with the anti-hSecR(51–65) polyclonal antibody52 (1:500 in PBS with
1% normal goat serum) followed by one PBS wash before being fixed with 2%
paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) in PBS for 15 min.
Coverslips were then washed three times with PBS containing 1% normal goat
serum and incubated for 1 h with 1:200 Alexa Fluor 488-conjugated anti-rabbit IgG
secondary antibody (Molecular Probes, Eugene, OR). Coverslips were washed three
times with PBS and mounted on microscope slides with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA). All above procedures were
performed at room temperature. Cells were visualized with a ×40 objective on a
Zeiss inverted microscope controlled by QED In Vivo software (Media Cybernetics,
Bethesda, MD). Quantification of receptor cell surface expression as fluorescence
percentage of wild-type secretin receptor was done by analyzing 6–8 cells for each
of the mutants using the ImageJ software (National Institutes of Health,
Bethesda, MD).
Receptor binding assay. The ability of the Cys5-antag, Cys6-antag, Cys7-antag,
and Cys10-antag probes to bind to the secretin receptor was assessed by a radi-
oligand competition-binding assay with intact receptor-expressing CHO-SecR cells
in 24-well tissue culture plates. In brief, CHO-SecR cells were grown to ~90%
confluence and were washed twice with Krebs–Ringers/HEPES (KRH) medium
(25 mm HEPES, pH 7.4, 104 mm NaCl, 5 mm KCl, 2 mm CaCl2, 1 mm KH2PO4,
1.2 mm MgSO4) containing 0.01% soybean trypsin inhibitor and 0.2% bovine
serum albumin. Cells were then incubated with a constant amount of radioligand,
125I-[Y10]sec(1–27) (~5 pM, ~10,000 cpm) in the absence and presence of
increasing concentrations (ranging from 0 to 1 μM) of each of the cysteine-
containing secretin antagonist probes for 1 h at room temperature (reaction
volume, 250 µL). Cells were then washed twice with ice-cold KRH medium con-
taining 0.01% soybean trypsin inhibitor and 0.2% bovine serum albumin to
separate bound from free radioligand before being lysed with 0.5 M NaOH and
quantified using a γ-spectrometer. Nonspecific binding was determined in the
presence of 0.1 µM unlabeled secretin and represented <15% of total radioligand
bound. Binding data were analyzed and plotted using the nonlinear regression
analysis program in the Prism software suite version 7.0 (GraphPad Software, San
Diego, CA) (Supplementary Fig. 8b). The same assay was also used to characterize
the binding activity of COS-1 cells transiently expressing the 14 new receptor
cysteine mutant constructs described above.
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Intracellular cAMP assay. The biological activity of the Cys5-antag, Cys6-antag,
Cys7-antag, and Cys10-antag probes were assessed by examining their ability to
stimulate cAMP responses in CHO-SecR cells50 using a time-resolved fluorescence-
based cAMP assay. In brief, ~8000 cells per well were grown in 96-well plates for
48 h prior to the assay. Cells were washed with PBS and stimulated with increasing
concentrations (ranging from 0 to 1 μM) of secretin or each of the cysteine-
containing secretin antagonist probes in KRH medium containing 0.01% soybean
trypsin inhibitor, 0.2% bovine serum albumin, 0.1% bacitracin, and 1 mM 3-
isobutyl-1-methylxanthine for 30 min at 37 °C. After incubation, the reaction
solution was aspirated and cells were lyzed with 6% ice-cold perchloric acid for 15
min with vigorous shaking. The cell lysates were adjusted to pH 6 with 30%
NaHCO3 and assayed for cAMP levels in a 384-well white Optiplate using a
LANCE cAMP kit from PerkinElmer (Boston, MA) (Supplementary Fig. 8c).
Antagonism of secretin-induced cAMP accumulation was also assessed by co-
incubation of increasing concentrations of each of the antagonists with 0.1 nM
secretin (Supplementary Fig. 8d). The cAMP concentration-response curves were
analyzed and plotted using the nonlinear regression analysis routine in Prism
Software Suite (GraphPad, San Diego, CA). The same assay was also used to
characterize the biological activity of COS-1 cells transiently expressing the 14 new
receptor cysteine mutant constructs described above.
Cysteine trapping. Four days prior to the cysteine trapping experiments, 5 × 104
COS-1 cells per well were plated in 24-well tissue culture plates. On the following
day, cells were transfected in batches with wild type, all the 61 cysteine secretin
receptor mutants that we previously used and 14 new receptor cysteine mutant
constructs described above using the polyethylenimine method as we have pre-
viously described23. On the day of assay, medium was removed by aspiration and
cells were washed once with DMEM containing 5% fetal clone II before being
incubated for 1.5 h at room temperature with 200 μL DMEM containing 5% fetal
clone II and 125I-Cys5-antag, or 125I-Cys6-antag or 125I-Cys7-antag or 125I-Cys10-
antag or the five secretin agonist probes we used previously23,24 (~100,000 cpm per
well) in the absence or presence of 0.1 μM secretin. After the medium was removed,
cells were washed once with ice-cold PBS and incubated with 80 µL SDS Laemmli
sample buffer with or without 0.1 M dithiothreitol on a shaker for 45 min. Cells
were then scraped and the lysates were transferred to 1.5 mL microcentrifuge tubes
using wide-bore tips. Samples were briefly sonicated to break the sticky DNA and
resolved in 10% SDS-polyacrylamide gels. Gels were dried, and bands of interest
were visualized by autoradiography with band densitometry analyzed by the
ImageJ software. The apparent molecular weights of the radioactive bands were
determined by interpolation on a plot of the mobility of the appropriate ProSieve
protein markers (Cambrex, Rockland, ME, USA) vs. the log values of their
apparent masses.
Modeling methods. The MD was based on the initial PDB model (6WI9) that
was available at the time. The missing stalk region was generated using Mod-
eller53 and refined using the loop modeling feature; the loop with the lowest
DOPE score54 (out of 2000 generated loops) was selected. The missing loops in
the G protein (L296-K307, C365-E370) were generated from the corresponding
loops in the β2-adrenergic receptor–G protein complex, PDB code 3SN655 by
fitting them with VMD56 to the flanking residues. The 3SN6 G protein X-ray
structure is 99% identical to the G protein used in this study; it generally gave a
lower root mean squared deviation value on molecular superposition than the
alternatives (e.g., PDB code 6b3j). The joining point was taken as the closest
atom pairs (usually separated by ~0.2 Å) that maintained an appropriate Cα–Cα
distance (3.8 ± 2 Å) across the join; selected residues spanning the join were
minimized using PLOP57 where additional refinement was desirable. The
S250–T263 loop was completed using the shorter loop from the adenosine A2A
receptor–G-protein complex, PDB code 5G5358. The helical domain (residues
A48—V204) was not visible in the cryo-EM structure and was omitted as in
earlier work12.
Systems preparation. The full-length model of the secretin:SecR:G protein:Nb35
complex was prepared for simulation with the CHARMM36 force field59, through
use of in-house python htmd60 and TCL (Tool Command Language) scripts. The
pdb2pqr61 and propka62 software were used to add hydrogen atoms appropriate
for a simulated pH of 7.0; the protonation of titratable side chains was checked by
visual inspection. The obtained structure was superimposed on the GLP-1R (PDB
ID 5VAI) from the OPM database63 so as to orient the receptor prior to insertion
in a rectangular prebuilt 125 Å × 116 Å 1-palmitoyl-2-oleyl-sn-glycerol-3-phos-
phocholine (POPC) bilayer; lipid molecules overlapping the receptor were
removed. TIP3P water molecules were added to the 125 Å × 116 Å × 178 Å simu-
lation box using the VMD Solvate plugin 1.5 (Solvate Plugin, Version 1.5. at
<http://www.ks.uiuc.edu/Research/vmd/plugins/solvate/). Overall charge neutrality
was maintained by adding Na+ and Cl− counter ions to a final ionic concentration
of 150 mM using the VMD Autoionize plugin 1.3 (Autoionize Plugin, Version 1.3.
at <http://www.ks.uiuc.edu/Research/vmd/plugins/autoionize/).
Systems equilibration and MD settings. ACEMD64 was used for both equili-
bration and MD productive simulations. Isothermal-isobaric conditions (Langevin
thermostat65 with a target temperature of 300 K and damping of 1 ps−1 and
Berendsen barostat66 with a target pressure 1 atm) were employed to equilibrates
the systems through a multistage procedure (integration time step of 2 fs). Initial
steric clashes between lipid atoms were reduced through 2500 conjugate-gradient
minimization steps, then a 2 ns MD simulation was run with a positional constraint
of 1 kcal mol−1 Å−2 on protein atoms and lipid phosphorus atoms. Subsequently,
20 ns of MD were performed constraining only the protein atoms. In the final
equilibration stage, only the protein backbone alpha carbons were constrained, to a
total simulation time of 100 ns.
Productive trajectories in the canonical ensemble (NVT) at 300 K (three replicas
of 0.94 μs, 0.88 μs, and 1.00 μs, respectively) were computed using a thermostat
damping of 0.1 ps−1 with an integration time step of 4 fs and the M-SHAKE
algorithm67 to constrain the bond lengths involving hydrogen atoms. The cut-off
distance for electrostatic interactions was set at 9 Å, with a switching function
applied beyond 7.5 Å. Long range Coulomb interactions were handled using the
particle mesh Ewald summation method53 (PME) by setting the mesh spacing to
1.0 Å. Trajectory frames were written every 100 ps of simulations.
Secretin partial unbinding and binding protocol. The secretin:SecR complex
(obtained removing both the G protein and Nb35) was prepared and equilibrated
as reported above. The secretin partial unbinding was then simulated in two dif-
ferent well-tempered metadynamics replicas68, biasing the distance between the
residues H1-R14 (secretin) and K1351.31-L3917.60 (SecR) centroids. Plumed2.369
was used to seed a Gaussian energy function every 1 ps (height= 0.1 kcal/mol,
width= 0.1 Å, with a biasfactor= 20), at a simulated temperature of 300 K, until
the distance reached 30 Å.
Starting from the final state of one of the two unbinding trajectories, the secretin
partial binding was simulated in six replicas supervising70 the same centroids
distance considered for the partial unbinding, during successive time windows of 2
ns.
To increase the overall MD sampling, each unbinding/binding replica was
grouped into 1 Å width bins according to the root mean square fluctuation (RMSF)
of the secretin Cα carbon to the initial positions. One frame was extracted from
each cluster and used as seed for a 30 ns long classic MD simulation, for a resulting
total MD time sampling of 6.4 μs.
MD analysis. Atomic contacts were computed using the GetContacts analysis tool
(at https://getcontacts.github.io/), with the donor-acceptor threshold distance set to
3.5 Å and the angle set to 120°. Videos were generated using VMD56 and avconv
(at https://libav.org/avconv.html). Root mean square deviation and RMSF values
were computed using VMD56 after superposition of the MD trajectories frames on
the alpha carbon of the TM domain (residues K1341.31 to L3917.60). VMD was also
employed to compute the Cβ–Cβ carbon distances on the 6.4 μs nonequilibrium
MD (secretin partial unbinding/binding), selecting the Cβ carbon of secretin
residues S2, T5, F6, and T7 and all the SecR Cβ atoms.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Data supporting the findings of this manuscript are available from the corresponding
authors upon reasonable request. A reporting summary for this article is available as a
Supplementary Information file.
Atomic coordinates and the cryo-EM density map have been deposited in the Protein
Data Bank (PDB) under accession numbers
PDB 6WI9 (low resolution model) and PDB 6WZG (high-resolution model), and
Electron Microscopy Data Bank (EMDB) accession numbers EMD-21683 (4.3 Å maps)
and EMD-21972 (high-resolution maps). Source data are provided with this paper.
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